Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the business’s stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $90.94, for a total transaction of $227,350.00. Following the sale, the chief executive officer directly owned 2,202,500 shares of the company’s stock, valued at approximately $200,295,350. The trade was a 0.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Price Performance

Shares of IRMD stock opened at $88.80 on Friday. iRadimed Corporation has a 1 year low of $50.00 and a 1 year high of $107.90. The firm has a fifty day moving average price of $98.15 and a 200-day moving average price of $93.46. The company has a market cap of $1.13 billion, a price-to-earnings ratio of 50.74 and a beta of 1.11.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The firm had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Equities research analysts expect that iRadimed Corporation will post 1.94 EPS for the current year.

iRadimed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Monday, February 23rd. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s payout ratio is presently 45.71%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IRMD. CWM LLC boosted its holdings in iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the period. Quarry LP bought a new position in iRadimed in the 3rd quarter worth $40,000. Farther Finance Advisors LLC boosted its holdings in iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 397 shares during the period. Tower Research Capital LLC TRC boosted its holdings in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the period. Finally, State of Alaska Department of Revenue bought a new position in iRadimed in the 3rd quarter worth $47,000. Institutional investors own 92.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Roth Mkm reaffirmed a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, iRadimed presently has an average rating of “Buy” and an average target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.